BRINGING NOVEL INVESTIGATIONAL TREATMENTS FOR ECZEMA, ASTHMA and cancer ONE STEP CLOSER TO APPROVAL
RAPT Therapeutics Reports First Quarter 2020 Financial Results
May 14, 2020
SOUTH SAN FRANCISCO, Calif., May 14, 2020 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage, immunology-based biopharmaceutical company focused on discovering, developing and commercializing oral small molecule therapies for patients with significant unmet needs in oncology and inflammatory diseases, today reported financial results for the first quarter ended March 31, 2020 and provided an update on recent operational and business progress.
“We continue to progress our programs during these challenging times. Our first priority is to protect our employees and our patients. We are practicing social distancing in the lab and conducting a good portion of our work remotely,” said Brian Wong, M.D., Ph.D., President and CEO of RAPT Therapeutics. “We remain in close contact with investigators from all of our clinical trial sites. As for our FLX475 trial, sites in Asia and some U.S. sites continue to enroll, although there has been some slowing in some regions as investigators adjust to SARS CoV2-related dynamics. We anticipate reporting initial results from our FLX475 Phase 1/2 trial in the second half of 2020.”
Dr. Wong continued, “We also are in contact with our RPT193 investigators. We expect to complete enrollment of patients with atopic dermatitis in the Phase 1b portion of our Phase 1 study and report results from the full Phase 1 study by the end of the year.”
Financial Results for the First Quarter Ended March 31, 2020
Net loss for the first quarter of 2020 was $13.1 million, compared to $9.2 million for the first quarter of 2019.
Revenue for the first quarter of 2020 was $0.9 million related to our collaboration with Hanmi Pharmaceutical LTD, signed in December 2019. There was no revenue in the comparable period of 2019.
Research and development expenses for the first quarter of 2020 were $10.7 million, compared to $7.9 million for the same period in 2019. The increase was primarily due to an increase in clinical costs related to FLX475 as it advances in development.
General and administrative expenses for the first quarter of 2020 were $3.3 million, compared to $1.7 million for the same period in 2019. The increase was primarily due to an increase in stock-based compensation expense, as well as an increase in legal, accounting and other fees associated with being a public company.
As of March 31, 2020, we had cash, cash equivalents and marketable securities of $138.2 million, which includes net proceeds of approximately $69.8 million from our follow-on public offering of 2,500,000 shares of common stock.
About RAPT Therapeutics, Inc.
RAPT Therapeutics is a clinical stage immunology-based biopharmaceutical company focused on discovering, developing and commercializing oral small molecule therapies for patients with significant unmet needs in oncology and inflammatory diseases. Utilizing its proprietary discovery and development engine, the Company is developing highly selective small molecules designed to modulate the critical immune drivers underlying these diseases. RAPT has discovered and advanced two unique drug candidates, FLX475 and RPT193, each targeting C-C motif chemokine receptor 4 (CCR4), for the treatment of cancer and inflammation, respectively. The Company is also pursuing a range of targets, including hematopoietic progenitor kinase 1 (HPK1) and general control nonderepressible 2 (GCN2), that are in the discovery stage of development.
This press release contains forward-looking statements. These statements relate to future events and involve known and unknown risks, uncertainties and other factors that may cause our actual results, performance or achievements to be materially different from any future performances or achievements expressed or implied by the forward-looking statements. Each of these statements is based only on current information, assumptions and expectations that are inherently subject to change and involve a number of risks and uncertainties. Forward-looking statements include, but are not limited to, statements about the impact of COVID-19 on the clinical development of FLX475 and RPT193 and the anticipated timing of clinical data. Detailed information regarding risk factors that may cause actual results to differ materially from the results expressed or implied by statements in this press release may be found in RAPT’s Form 10-K filed with the Securities and Exchange Commission on March 30, 2020 and subsequent filings made by RAPT with the Securities and Exchange Commission. These forward-looking statements speak only as of the date hereof. RAPT disclaims any obligation to update these forward-looking statements.
RAPT Media Contact:
RAPT Investor Contact:
|RAPT THERAPEUTICS, INC.|
|CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS|
|(In thousands, except share and per share data)|
|Three Months Ended|
|Research and development||10,683||7,870|
|General and administrative||3,289||1,674|
|Total operating expenses||13,972||9,544|
|Loss from operations||(13,037||)||(9,544||)|
|Other income, net||135||356|
|Net loss before taxes||(12,902||)||(9,188||)|
|Provision for income taxes||237||—|
|Other comprehensive income:|
|Foreign currency translation adjustment||204||—|
|Unrealized loss on marketable securities||(217||)||—|
|Total comprehensive loss||$||(13,152||)||$||(9,188||)|
|Net loss per share, basic and diluted||$||(0.56||)||$||(13.28||)|
|Weighted average number of shares used in computing net loss per share, basic and diluted||23,266,063||691,834|
|RAPT THERAPEUTICS, INC.|
|CONDENSED CONSOLIDATED BALANCE SHEETS|
|March 31,||December 31,|
|Cash and cash equivalents||$||91,529||$||77,383|
|Prepaid expenses and other current assets||3,685||3,123|
|Total current assets||146,894||80,506|
|Property and equipment, net||3,606||3,707|
|Liabilities and stockholders' equity|
|Other current liabilities||436||471|
|Total current liabilities||13,442||9,256|
|Deferred rent, net of current portion||2,218||2,225|
|Deferred revenue, non-current||3,300||—|
|Additional paid-in capital||307,009||235,049|
|Accumulated other comprehensive income||7||20|
|Total stockholders' equity||131,929||73,121|
|Total liabilities and stockholders' equity||$||150,889||$||84,602|
« back to news page